- Home
- KC vs HRMY Comparison
KC vs HRMY Comparison
Compare KC & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KC | HRMY |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | China | United States |
| Employees | N/A | 293 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.4B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KC | HRMY |
|---|---|---|
| Price | $9.42 | $40.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $18.00 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 1.1M | 866.4K |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 1.84 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $30.93 | $19.75 |
| Revenue Next Year | $20.45 | $12.88 |
| P/E Ratio | ★ N/A | $22.46 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $8.35 | $25.52 |
| 52 Week High | $18.52 | $43.49 |
Technical Indicators
Market Signals| Indicator | KC | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 39.51 | 46.60 |
| Support Level | $9.29 | $37.30 |
| Resistance Level | $11.06 | $43.38 |
| Average True Range (ATR) | 0.25 | 1.18 |
| MACD | -0.01 | -0.33 |
| Stochastic Oscillator | 10.81 | 13.92 |
Price Performance
Historical ComparisonAbout KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.